J M Chi1, M Mackay2, A Hoang3, K Cheng4, C Aranow2, J Ivanidze5, B Volpe6, B Diamond2, P C Sanelli7,8. 1. From the Department of Radiology (J.M.C., K.C.), Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, New York jchi2@northwell.edu. 2. Feinstein Institute for Medical Research (M.M., C.A., B.D.), The Center for Autoimmune, Musculoskeletal and Hematopoietic Diseases, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, New York. 3. Department of Radiology (A.H.), Northwell Health, Manhasset, New York. 4. From the Department of Radiology (J.M.C., K.C.), Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, New York. 5. Department of Radiology (J.I.), Weill Cornell Medical College, New York, New York. 6. Feinstein Institute for Medical Research (B.V.), The Center for Biomedical Science, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, New York. 7. Feinstein Institute for Medical Research (P.C.S.), The Center for Health Innovations and Outcomes Research, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, New York. 8. Department of Radiology (P.C.S.), Northwell Health, Imaging Clinical Effectiveness and Outcomes Research Program, Manhasset, New York.
Abstract
BACKGROUND AND PURPOSE: Neuropsychiatric systemic lupus erythematosus refers to central and peripheral nervous system involvement, which may occur secondary to antineuronal antibodies crossing the blood-brain barrier that preferentially target cells in the hippocampus leading to abnormal hypermetabolism and atrophy. Thus, we hypothesized that alterations in BBB permeability, detected on dynamic contrast-enhanced MR imaging, occur in the hippocampus in patients with systemic lupus erythematosus before development of neuropsychiatric systemic lupus erythematosus. MATERIALS AND METHODS: Six patients with systemic lupus erythematosus without neuropsychiatric systemic lupus erythematosus and 5 healthy controls underwent dynamic contrast-enhanced MR imaging with postprocessing into BBB permeability parameters (K trans and Ve) and CBF. Standardized methods selected ROI sampling of the abnormal brain regions detected on FDG-PET. The mean and SD of K trans, Ve, and CBF were calculated. Linear regression and nonparametric Spearman rank correlation analyses of K trans and Ve with CBF were performed. Dynamic contrast-enhanced curves and the area under the curve were generated for each brain region. Student t test comparisons were performed. RESULTS: Quantitative data revealed that patients with systemic lupus erythematosus have statistically increased K trans (P < .001) and Ve (P < .001) compared with controls. In patients with systemic lupus erythematosus, statistically significant positive correlations were seen between K trans (P < .001) and Ve (P < .001) with CBF. Furthermore, the mean area under the curve revealed statistically increased BBB permeability in the hippocampus (P = .02) compared with other brain regions in patients with systemic lupus erythematosus compared with controls. CONCLUSIONS: These initial findings are proof-of-concept to support the hypothesis that patients with systemic lupus erythematosus have increased BBB permeability, specifically in the hippocampus, compared with other brain regions. These findings may advance our understanding of the underlying pathophysiology affecting the brain in autoimmune diseases.
BACKGROUND AND PURPOSE:Neuropsychiatric systemic lupus erythematosus refers to central and peripheral nervous system involvement, which may occur secondary to antineuronal antibodies crossing the blood-brain barrier that preferentially target cells in the hippocampus leading to abnormal hypermetabolism and atrophy. Thus, we hypothesized that alterations in BBB permeability, detected on dynamic contrast-enhanced MR imaging, occur in the hippocampus in patients with systemic lupus erythematosus before development of neuropsychiatric systemic lupus erythematosus. MATERIALS AND METHODS: Six patients with systemic lupus erythematosus without neuropsychiatric systemic lupus erythematosus and 5 healthy controls underwent dynamic contrast-enhanced MR imaging with postprocessing into BBB permeability parameters (K trans and Ve) and CBF. Standardized methods selected ROI sampling of the abnormal brain regions detected on FDG-PET. The mean and SD of K trans, Ve, and CBF were calculated. Linear regression and nonparametric Spearman rank correlation analyses of K trans and Ve with CBF were performed. Dynamic contrast-enhanced curves and the area under the curve were generated for each brain region. Student t test comparisons were performed. RESULTS: Quantitative data revealed that patients with systemic lupus erythematosus have statistically increased K trans (P < .001) and Ve (P < .001) compared with controls. In patients with systemic lupus erythematosus, statistically significant positive correlations were seen between K trans (P < .001) and Ve (P < .001) with CBF. Furthermore, the mean area under the curve revealed statistically increased BBB permeability in the hippocampus (P = .02) compared with other brain regions in patients with systemic lupus erythematosus compared with controls. CONCLUSIONS: These initial findings are proof-of-concept to support the hypothesis that patients with systemic lupus erythematosus have increased BBB permeability, specifically in the hippocampus, compared with other brain regions. These findings may advance our understanding of the underlying pathophysiology affecting the brain in autoimmune diseases.
Authors: Richard E Latchaw; Howard Yonas; George J Hunter; William T C Yuh; Toshihiro Ueda; A Gregory Sorensen; Jeffrey L Sunshine; Jose Biller; Lawrence Wechsler; Randall Higashida; George Hademenos Journal: Stroke Date: 2003-04 Impact factor: 7.914
Authors: Page I Wang; Patricia C Cagnoli; William J McCune; Tobias Schmidt-Wilcke; Suzan E Lowe; Courtney C Graft; Stephen S Gebarski; Thomas L Chenevert; Shokoufeh Khalatbari; James D Myles; Kuanwong Watcharotone; Paul Cronin; Pia C Sundgren Journal: Acad Radiol Date: 2012-05-17 Impact factor: 3.173
Authors: Michelle Petri; Mimi Y Kim; Kenneth C Kalunian; Jennifer Grossman; Bevra H Hahn; Lisa R Sammaritano; Michael Lockshin; Joan T Merrill; H Michael Belmont; Anca D Askanase; W Joseph McCune; Michelene Hearth-Holmes; Mary Anne Dooley; Joan Von Feldt; Alan Friedman; Mark Tan; John Davis; Mary Cronin; Betty Diamond; Meggan Mackay; Lisa Sigler; Michael Fillius; Ann Rupel; Frederick Licciardi; Jill P Buyon Journal: N Engl J Med Date: 2005-12-15 Impact factor: 91.245
Authors: Pamela Munguía-Realpozo; Mario García-Carrasco; Claudia Mendoza-Pinto; María de Lourdes Galaviz-Silva; Ivet Etchegaray-Morales; Socorro Méndez-Martínez; Álvaro José Montiel-Jarquín; Luis G Vázquez de Lara; Luis H Silveira Journal: Clin Rheumatol Date: 2022-05-27 Impact factor: 3.650
Authors: John G Hanly; Alexandra Legge; Lyna Kamintsky; Alon Friedman; Javeria A Hashmi; Steven D Beyea; John Fisk; Antonina Omisade; Cynthia Calkin; Tim Bardouille; Chris Bowen; Kara Matheson; Marvin J Fritzler Journal: Lupus Sci Med Date: 2022-06
Authors: Alexis Wilson; Carmen A Velasco; Guy W Herbert; Selita N Lucas; Bethany N Sanchez; José M Cerrato; Michael Spilde; Quan-Zhen Li; Matthew J Campen; Katherine E Zychowski Journal: J Toxicol Environ Health A Date: 2021-03-07
Authors: T A Arsiwala; S A Sprowls; K E Blethen; C E Adkins; P A Saralkar; R A Fladeland; W Pentz; A Gabriele; B Kielkowski; R I Mehta; P Wang; J S Carpenter; M Ranjan; U Najib; A R Rezai; P R Lockman Journal: Neoplasia Date: 2021-06-14 Impact factor: 6.218
Authors: Mark W DiFrancesco; Gregory Lee; Mekibib Altaye; Dean W Beebe; Jamie Meyers-Eaton; Hermine I Brunner Journal: Arthritis Res Ther Date: 2020-06-08 Impact factor: 5.156